Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|December 2, 2014
- Pharmaceutical Technology-12-02-2014
- Volume 38
- Issue 12
VIDEOJET Thermal Ink Printer Offers Increased Resolution
VIDEOJET’s thermal ink jet printer, the Videojet 8610, is designed for high-resolution coding with MEK-based fluids on non-porous packaging, including films, foils, plastics, and coated stocks.
VIDEOJET’s thermal ink jet printer, the Videojet 8610, is designed for high-resolution coding with MEK-based fluids on non-porous packaging, including films, foils, plastics, and coated stocks.
The printer features three components: a controller with user interface, an industrial printhead featuring a Cartridge Readiness System, and a disposable ink-jet cartridge. It has wear-resistant parts and no calibration or tuning requirements.
Each cartridge change provides a new print array. Code Assurance assists operators in getting the correct code on the product, the company reports.
VIDEOJET
Articles in this issue
almost 12 years ago
Sartorius Bioreactor and Microbial Fermenter Increases Efficiencyalmost 12 years ago
Ross Planetary Mixers Increase Mixing Optionsalmost 12 years ago
The Bio/Pharma Working Lifealmost 12 years ago
FDA Realigns Drug Inspection and Manufacturing Oversightalmost 12 years ago
Fitzpatrick Roll Compaction Series Improves Accuracyalmost 12 years ago
Drug Scandals Impact Industry in Japanalmost 12 years ago
Securing the Single-Use Supply Chainalmost 12 years ago
Improving Job Market Creates Opportunity for Changealmost 12 years ago
FDA Approves Novel Treatments in 2014almost 12 years ago
Novel Technologies Win CPhI Pharma AwardsRelated to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Complying with International Pharmacopoeias
3
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5